Abstract: The subject invention involves process for making fuctionalized oxazolidinones having structure (1) wherein: (a) R1 and R2 are each independently selected from hydrogen, alkyl, aryl and heterocycle, or R1 and R2 are attached to form a cycloalkyl, aryl or heterocyclic ring; (b) R3 is selected from primary and secondary alkly (—R6), —SO2—R4, and —C(O)NH—R5; (c) R4 is aryl; and (d) R5 is alkyl or aryl; the process comprising a reaction step carried out in a reaction mixture, wherein an oxazolidinone is reacted with an electrophile selected from R6-Br, R6-I, R4-SO2Cl, and R5-NCO; the reaction mixture comprising a non-protic and non-oxidizing solvent and potassium fluoride on alumina; and without the presence of a substantial amount of a strong base in the reaction mixture. The subject invention also involves libraries of functionalized oxazolidinone compounds and their preparation using such processes.

Abstract: The subject invention involves chess pieces made primarily from hardware components and chess sets of such chess pieces. Each chess piece comprises a center shaft component comprising a vertical threaded rod having a bottom end, a top end, and a surface from the rod's bottom end to its top end that is partially or wholly cylindrical and threaded. The center shaft component optionally comprises a head at either its bottom or top end. Each chess piece also comprises holed components, each holed component having a hole through which or into which the center shaft component projects. The holed components are stacked along the length of the center shaft component. All the holed components are secured in place by one or more holed components which are nuts having threads complementary to those of the threaded rod, and optionally by the head of the center shaft component.

Abstract: The subject invention involves novel acyl isothiocyanate resins of formula (I) and processes for making them: (a) starting with a phenyl carboxy resin, treating the resin with any reagent that converts the carboxy to an acyl halide, followed by treatment with tetranikylammonium thiocyanate or an alkali metal salt thereof, to provide the acyl isothiocyanate resin. The subject invention also involves processes for making guanidine compounds and related cyclized compounds using an acyl isothiocyanate resin, comprising the following steps: (b) reacting the acyl isothiocyanate resin with a primary amine; (c) reacting the product from Step (b) with a sulfur activating agent and ammonia or a primary or secondary amine; (d) treating the product from Step (c) with a strong base or medium strength acid to cleave product from the resin, providing the guanidine compound or/and the related cyclized compound.

Abstract: The subject invention involves processes for making 1-aminohydantoin compounds using a solid support resin, comprising the following steps; (a) preparing a resin-bound protected &agr;-hydrazinyl ester; (1) by reacting the resin with an &agr;-bromo carboxylic acid, then with a protected hydrazine; or (2) by reacting the resin with a protected &agr;-hydrazinyl carboxylic acid; (b) preparing a resin-bound imine by removing the blocking group from the hydrazinyl moiety, then reacting the unprotected hydrazinyl moiety with an aldehyde or ketone; (c) preparing a resin-bound secondary urea: (1) by reacting the imine with p-nitrophenylchloroformate or trisphosgene, then with a primary amine; or (2) by reacting the imine with an isocyanate, and (d) preparing the 1-aminohydantoin compound by removing the secondary urea from the resin and cyclizing it.

Abstract: Compounds having the general structure: which are effective antimicrobial agents.

Abstract: The subject invention involves compounds having the structure: wherein the C.sub..alpha. --N.sub..beta. and C.sub.5 -C.sub.6 bonds are independently single or double bonds, R1 is selected from alkyl, aryl, and heterocycle; R2-R13 are independently selected from hydrogen and other substituents; and pharmaceutically-acceptable salts thereof. The subject invention also involves pharmaceutical compositions containing such compounds, and methods for treating or preventing diseases and disorders using such compounds.

Abstract: The present invention provides a firm, mild, good performing, low-smear semi-solid or solid dishwashing product. The rheology of the dishwashing product is such that structural elements have been separated from functional elements to obtain best structure properties and in-use properties. By using an interlocking mesh of carboxylic acid and/or neutralized carboxylic acid fibers and/or platelets to provide a support structure, the semi-solid or solid dishwashing product can be loaded with superior performing dishcare materials (e.g., mild surfactants) and appearance enhancers without dependence on surfactant-water phase behavior to provide the support structure. As a result, the present dishwashing product is milder than semi-solid dishwashing products currently on the market. The support structure of the present product, and preferably the use of hygroscopic surfactants, provide a product with lower smear than current gel dishwashing products.

Abstract: The performance of photobleaches such as the zinc phthalocyanines is enhanced by means of alkylene amino/carboxylate or alkylene amino/phosphonate chelants. Thus, sulfonated zinc phthalocyanine plus diethylenetriamine pentaacetate provide enhanced photobleaching of laundered fabrics. Detergent compositions comprising the improved photobleach systems are provided.

Abstract: Disclosed are compositions of laundry detergent bars that do not develop undesirable brittleness during storage. The disclosed compositions comprise alkyl sulfate surfactant, preferably coconut alkyl sulfate, and polyethylene glycol. The polyethylene glycol prevents the development of undesirable brittleness in such alkyl sulfate-containing laundry bars.

Abstract: The subject invention involves laundry bar compositions comprising:(a) from about 20% to about 70% surfactant, the surfactant consisting essentially of from about 50% to 100% soap and from 0% to about 50% alkylbenzene sulfonate;(b) from about 12% to about 24% water;(c) from about 61/4% to about 20% calculated excess alkali metal carbonate;(d) from about 2% to about 20% water-soluble inorganic strong-electrolyte salt;(e) from 0% to about 4% whole-cut starch;(f) from 0% to about 8% added alkali metal bicarbonate;(g) from 0% to about 30% phosphate builder;(h) from 0% to about 40% insoluble filler; and(j) from 0% to about 15% other ingredients selected from other builders, chelants, enzymes, soil release polymers, dye transfer inhibiting agents, fabric softeners, bleaching agents, gums, thickeners, binding agents, other starches, soil suspending agents, optical brighteners, colorants and opacifiers, perfumes, bluing agents, and mixtures thereof;the bar having a firmness measurement of at least about 10 kg.

Abstract: The subject invention involves methods and compositions for reducing non-ultraviolet-induced free radical damage in mammals comprising administering to a mammal a composition comprising a safe and effective amount of a compound selected from 2,4-dienoic acid esters of tocopherols and mixtures of such compounds, optionally in combination with chelating agents and/or anti-inflammatory agents.

Abstract: This invention involves involves the use of compounds having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo;for preventing or treating of disorders modulated by alpha-2 adrenoceptors.The subject invention also involves novel compounds and compositions.

Abstract: The subject invention relates to compounds having the structure: ##STR1## wherein (a) n is an integer from 1 to about 3;(b) X and Y are each independently selected from O, S and CH.sub.2, with at least one of X and Y being O or S;(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and(d) R' is selected from hydrogen, methyl, cyano, and halo; pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.

Abstract: The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: ##STR1## wherein (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl, unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; and halo.The subject invention also involves the use of such compounds for preventing or treating other respiratory, ocular and/or gastrointestinal disorders.

Abstract: The subject invention relates to compounds having the structure: ##STR1## as defined in the claims, and to pharmaceutical compositions containing such compounds, and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.

Abstract: The present invention relates to methods and compositions for prevention or treatment of bone loss due to periodontal disease, oral osseous surgery, periodontal flap surgery, tooth extraction, dental implants, or scaling and root planing comprising topical administration, to mucosal tissues of the oral cavity, of a composition having from about 0.001% to about 0.2% ketorolac in the oral cavity.

Abstract: The subject invention involves processes for making granular compositions comprising soil release polymers, the polymers comprising at least about 10% of substantially linear esters having a backbone; the esters being uncapped or end-capped on one or both ends of the backbone; the esters comprising in their backbones oxyalkyleneoxy units and hydrophobic aryldicarbonyl units; the esters having a molecular weight of from about 500 to about 20,000; the polymers if in solid state having the tendency when exposed to moisture to spontaneously rearrange from an amorphous form which is readily soluble in water to a crystalline form which is relatively insoluble in water; the process comprising the following steps:a) taking the soil release polymers, in which are dispersed from 0% to about 25% alkylaryl or alkyl sulfonate crystallization-reducing stabilizers, in molten state at a temperature of at least about 180.degree. C.

Abstract: The subject invention involves laundry compositions comprising:(a) from about 10% to about 35%, anionic surfactant,(b) at least about 0.5% polyethylene glycol,(c) at least about 5% water, and(d) at least about 5% phosphate builder; the composition being in the form of a bar; and processes for making such bars.

Abstract: The subject invention involves a method of reducing non-ultraviolet-induced free radical damage in mammals comprising administering to a mammal a composition comprising a safe and effective amount of a compound selected from 2,4-dienoic acid esters of tocopherols and mixtures of such compounds.

Abstract: The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo.The subject invention also involves the use of such compounds for preventing or treating other respiratory, ocular and/or gastrointestinal disorders. The subject invention also involves novel compounds having the above structure wherein R' is hydrogen or fluoro or cyano.